A detailed history of Fmr LLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 11,112,391 shares of SWTX stock, worth $394 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
11,112,391
Previous 11,068,026 0.4%
Holding current value
$394 Million
Previous $545 Million 23.16%
% of portfolio
0.03%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$36.06 - $47.62 $1.6 Million - $2.11 Million
44,365 Added 0.4%
11,112,391 $419 Million
Q1 2024

May 13, 2024

BUY
$36.5 - $52.5 $9.45 Million - $13.6 Million
258,791 Added 2.39%
11,068,026 $545 Million
Q4 2023

Feb 13, 2024

BUY
$18.94 - $37.24 $27 Million - $53 Million
1,423,764 Added 15.17%
10,809,235 $395 Million
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $160,822 - $218,279
6,956 Added 0.07%
9,385,471 $217 Million
Q2 2023

Aug 11, 2023

BUY
$23.15 - $32.71 $85,608 - $120,961
3,698 Added 0.04%
9,378,515 $246 Million
Q1 2023

May 11, 2023

BUY
$24.97 - $34.05 $367,733 - $501,454
14,727 Added 0.16%
9,374,817 $241 Million
Q4 2022

Feb 13, 2023

SELL
$21.73 - $28.72 $1,521 - $2,010
-70 Reduced -0.0%
9,360,090 $243 Million
Q3 2022

Nov 10, 2022

BUY
$24.1 - $39.66 $46.9 Million - $77.3 Million
1,948,120 Added 26.28%
9,360,160 $263 Million
Q2 2022

Aug 12, 2022

BUY
$18.36 - $60.07 $25.1 Million - $82 Million
1,365,831 Added 22.59%
7,412,040 $182 Million
Q1 2022

May 13, 2022

BUY
$48.97 - $65.46 $103 Million - $137 Million
2,099,889 Added 53.21%
6,046,209 $341 Million
Q4 2021

Feb 14, 2022

SELL
$53.3 - $75.84 $3.67 Million - $5.22 Million
-68,800 Reduced 1.71%
3,946,320 $245 Million
Q3 2021

Nov 15, 2021

BUY
$62.66 - $88.26 $2.94 Million - $4.14 Million
46,900 Added 1.18%
4,015,120 $255 Million
Q2 2021

Aug 13, 2021

BUY
$67.45 - $85.63 $268 Million - $340 Million
3,968,220 New
3,968,220 $327 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.21B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.